For the third quarter of 2026, analysts expect Insmed to report consensus revenue of $499.06 million and an EPS of -$0.34, with the current stock price of $93.39 trading well below the average analyst price target of $204.15.
Investors are laser-focused on the commercial performance of BRINSUPRI (brensocatib), specifically its sequential growth following its 2025 FDA approval and recent launch in Japan.
The company recently raised its 2026 BRINSUPRI revenue guidance to a range of $1.25 billion to $1.40 billion, reflecting high demand for the first-in-class NCFB therapy.
Management's commentary on the trajectory toward cash flow positivity by 2027 and pipeline progress for TPIP remain critical components of the long-term growth narrative.